Erythropoietic therapy: Cost efficiency and reimbursement

American Journal of Health-System Pharmacy

Volumn 64, Issue 16 SUPPL., 2007, Pages

  Jaspan, David ^a  

^a ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Anemia; Blood; Economics; Education; Epoetin alfa; Hematopoietic agents; Hospitals; Reimbursement; Surgery; Toxicity

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; CYANOCOBALAMIN; DESMOPRESSIN ACETATE; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHYTOMENADIONE; RECOMBINANT ERYTHROPOIETIN; TRANEXAMIC ACID; VASOPRESSIN;

ANEMIA; AWARENESS; BLOOD AUTOTRANSFUSION; BLOOD CONSERVATION; BLOOD SALVAGE; BLOOD TRANSFUSION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; ECONOMIC EVALUATION; EDUCATION PROGRAM; HAZARD; HEALTH PERSONNEL ATTITUDE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL INFECTION; HUMAN; MULTIPLE ORGAN FAILURE; OPERATING ROOM; PERIOPERATIVE PERIOD; PHLEBOTOMY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REIMBURSEMENT; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 34547895114     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070246     Document Type: Conference Paper

References (84)

1. Watch Tower Bible and Tract Society. Jehovah's Witnesses and the Question of Blood. Brooklyn, NY: Watchtower Bible and Tract Society; 1977.
2. Woolley S. Jehovah's Witnesses in the emergency department: what are their rights? Emergency Medical Journal. 2005; 22:869-71.
3. Vamvakas EC. Epidemiology of red blood cell utilization. Transfus Med Rev. 1996; 10:44-61.
4. Stover EP, Siegel LC, Parks R et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology. 1998; 88:327-33.
5. Shander A, Moskowitz D, Rijhwani TS. The safety and efficacy of "bloodless" cardiac surgery. Semin Cardiothoracic Vasc Anesth. 2005; 9:53-63.
6. Reger TB, Roditski D. Bloodless medicine and surgery for patients having cardiac surgery. Crit Care Nurse. 2001; 21:35-44.
7. Corwin HL, Gettinger A, Pearl RG et al. The CRIT Study: Anemia and blood transfusion in the critically ill-current clinical practice in the United States. Crit Care Med. 2004; 32:39-52.
8. Amin M, Wilson K, Tinmouth A et al. Does a perception of increased blood safety mean increased blood transfusion? An assessment of the risk compensation theory in Canada. BMC Public Health. 2004; 4:20.
9. Jackson WL Jr, Shorr AF. Blood transfusion and the development of acute respiratory distress syndrome: more evidence that blood transfusion in the intensive care unit may not be benign. Crit Care Med. 2005; 33:1420-1. Editorial.
10. McClelland B, Contreras M. Appropriateness and safety of blood transfusion. BMJ. 2005; 330:104-5. Editorial.
11. Goodman C, Chan S, Collins P et al. Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment - final report. Transfusion. 2003; 43: 3S-46S.
12. Nouwairi NS. The risks of blood transfusions and the shortage of supply leads to the quest for blood substitutes. AANA J. 2004; 72:359-64.
13. American Red Cross makes emergency appeal. Regional blood shortage potentially threatens elective surgeries. redcrossgulfcoast.org/news/06/060706. htm (accessed 2007 Feb 10).
14. Greater Chesapeake and Potomac (GC & P) Blood Services Region of the American Red Cross. Critical blood shortage continues throughout region. August 28, 2006. www.my-redcross.org/documents/08282006PressRelease.pdf (accessed 2007 Feb 10).
15. Blood shortage. October 25, 2000. www.pbs.org/newshour/bb/health/july- dec00/blood_shortage.html (accessed 2007 Feb 10).
16. The cost of blood: Multidisciplinary conference for a standard methodology. Transfus Med Rev. 2005; 19:66-78.
17. Cantor SB, Hudson DV Jr, Lichtiger B et al. Costs of blood transfusion: A process-flow analysis. J Clin Oncol. 1998; 16:2364-70.
18. Crémieux PY, Barrett B, Anderson K et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol. 2000; 18:2755-61.
19. Forbes JM, Anderson MD, Anderson GF et al. Blood transfusion costs: A multicenter study. Transfusion. 1991; 31:318-23.
20. Lubarsky DA, Hahn C, Bennett DH et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg. 1994; 79:629-37.
21. Tretiak R, Laupacis A, Riviere M et al. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. CMAJ. 1996; 154:1501-8.
22. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med. 2003; 13:205-18.
23. Linden JV, Wagner K, Voytovich AE et al. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion. 2000; 40:1207-13.
24. Linden JV, Paul B, Dressier KP. A report of 104 transfusion errors in New York State. Transfusion. 1992; 32:601-6.
25. Stainsby D, Cohen H, Jones H et al. Serious hazards of transfusion annual report 2004. ISBN 0 9532 789 7 2, 21 November, 2005.
26. AuBuchon JP. Meeting transfusion safety expectations. Ann Intern Med. 2005; 143:537-8. Editorial.
27. Busch MP, Glynn SA, Stramer SL et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005; 45:254-64.
28. Synder EL, Dodd RY. Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Program. 2001; 1:433-42.
29. Alter HJ. Emerging, re-emerging and submerging infectious threats to the blood supply. Vox Sang. 2004; 87(Suppl. 2):S56-S61.
30. Farge D, Lebbé C, Marjanovic Z et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Transplantation. 1999; 67:1236-42.
31. Schennach H, Schonitzer D, Wachter H et al. Blood donations and viruses. Lancet. 1997; 349:1327-8.
32. Cannon MJ, Dollard SC, Smith DK et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. 2001; 344:637-43.
33. Croce MA, Tolley EA, Claridge JA et al. Transfusions result in pulmonary morbidity and death after a moderate degree of injury. J Trauma. 2005; 59:19-24.
34. Taylor RW, Manganaro L, O'Brien J et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med. 2002; 30:2249-54.
35. Vincent JL, Baron J-F, Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002; 288:1499-1507.
36. Shander A. Surgery without blood. Crit Care Med. 2003; 31(suppl):S708-14.
37. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic transfusion. Transfusion. 2003; 43:668-76.
38. Weber EWG, Slappendel R, Hemon Y et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol. 2005; 22:249-57.
39. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002; 288:2827-35.
40. Feagan BG, Wong CJ, Kirkley A et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000; 133:845-54.
41. Goldberg MA. Perioperative epoetin alfa increases red blood cell mass and reduces exposure to transfusions: results of randomized clinical trials. Semin Hematol. 1997; 34:41-7.
42. Lofthouse RA, Boitano MA, Davis JR et al. Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction. Journal of the Southern Orthopaedic Association. 2000; 9:175-81.
43. Pierson JL, Hannon TJ, Earles DR. A blood-conservation algorithm to reduce blood transfusions after total hip and knee arthroplasty. J Bone Joint Surg Am. 2004; 86A:1512-18.
44. Rosenblum N, Levine MA, Handler T et al. The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy. J Urol. 2000; 163:829-33.
45. Stowell CP, Chandler H, Jove M et al. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics. 1999; 22(suppl):S105-12.
46. Gohel MS, Bulbulia RA, Slim FJ et al. How to approach major surgery where patients refuse blood transfusion (including Jehovah's Witnesses). Ann R Coll Surg Engl. 2005; 87:3-14.
47. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Haematol. 2002; 15:399-409.
48. Killian AD, Gupta V, Goetz AE. Cost analysis of erythropoietic- stimulating therapy dosing in oncology inpatients. Ann Pharmacother. 2006; 40:421-6.
49. Package insert. Procrit (epoetin alfa). Raritan, NJ: Ortho Biotech Products, January 2005.
50. Granetto C, Ricci S, Martoni A et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep. 2003; 10:1289-96.
51. National Comprehensive Cancer Network. Cancer and treatment-related anemia. Version 2. 2005. www.nccn.org (accessed 2007 Feb 14).
52. Package insert. Aranesp® (darbepoetin alfa). Thousand Oaks, CA: Amgen Inc., March 2005.
53. Herrington JD, Davidson SL, Tomita DK et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health-Syst Pharm. 2005; 62:54-62.
54. Crémieux PY, Fastenau JM, Kosicki G et al. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J Manag Care Pharm. 2004; 10:531-7.
55. Mark TL, McKenzie RS, Fastenau J et al. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin. 2005; 21:1347-54.
56. Gosselin A, Lefebvre P, Duh MS et al. Dosing patterns and transfusion use in cancer patients treated with erythropoietic agents: Results of an observational study of over 8,000 patients. Blood. 2005; 106:872a. Abstract 3118.
57. Harley C, Muser E, Nelson M et al. Poster presented at the 40th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition December 4-8, 2005; Las Vegas, NV.
58. Harris HM, DelAguila M, Lopez JM et al. Poster presented at the Academy of Managed Care Pharmacy 2005 Educational Conference October 5-8, 2005; Nashville, TN.
59. Duh MS, Vekeman F, McKenzie RS et al. Real-world dosing and cost considerations of epoetin alfa and darbepoetin alfa in the inpatient hospital setting. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; October 26-29, 2006; St. Louis, MO.
60. Food and Drug Administration Center for Drug Administration and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) FDA Alert [3/09/2007]. www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm (accessed 2007 Apr 17).
61. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10: Study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. http://frejacms.au.dk/dahanca/get_media_file.pdf (accessed 2007 Apr 17).
62. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy. www.clinicalstudyresults.org/ documents/company-study_21557_0.pdf (accessed 2007 Apr 17).
63. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25:1027-32.
64. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemia patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23:5960-72.
65. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
66. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.
67. Policy & Practice News. Medicare announces review of coverage policy for Medicare policy on covering anemia medications linked to side effects. www.hematology.org/policy/news/anemia_meds_03152007.cfm (accessed 2007 Apr 10).
68. Martyn V, Farmer SL, Wren MN et al. The theory and practice of bloodless surgery. Transfus Apheresis Sci. 2002; 27:29-43.
69. Keating EM, Meding JB. Perioperative blood management practices in elective orthopaedic surgery. J Am Acad Orthop Surg. 2002; 10:393-400.
70. Shander A, Moskowitz D, Rijhwani TS. The safety and efficacy of "bloodless" cardiac surgery. Semin Cardiothoracic Vasc Anesth. 2005; 9:53-63.
71. Rosencher N, Kerkkamp HE, Macheras G et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003; 43:459-69.
72. Shander A, Rijhwani TS. Clinical outcomes in cardiac surgery: conventional surgery versus bloodless surgery. Anesth Clin North Am. 2005; 23:327-45.
73. Helm RE, Rosengart TK, Gomez M et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg. 1998; 65:125-36.
74. Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery: erythropoietin and antifibrinolytics. Can J Anaesth. 2001;48:S24-31.
75. Donahue MA, Price PM. Aprotinin: antifibrinolytic and anti-inflammatory mechanisms of action in cardiac surgery with cardiopulmonary bypass. Dynamics. 2002; 13:16-23.
76. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep. 2005; 4:368-72.
77. 2006 Red Book. Montvale, NJ: Medical Economics, 2006.
78. Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA. 1991; 265:86-90.
79. Stover EP, Siegel LC, Body SC at al. Institutional variability in red blood cell conservation practices for coronary artery bypass graft surgery. Institutions of the MultiCenter Study of Perioperative Ischemia Research Group. J Cardiothorac Vasc Anesth. 2000; 14:171-6.
80. Audet AM ACPM. Red blood cell transfusion practices in patients undergoing orthopedic surgery: a multi-institutional analysis. Orthopedics. 1998; 21:851-8.
81. Poses RM, Berlin JA, Noveck H et al. How you look determines what you find: severity of illness and variation in blood transfusion for hip fracture. Am J Med. 1998; 105:198-206.
82. Myers E, Grady PO, Dolan AM. The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg. 2004; 124:699-701.
83. Nissenson AR, Wade S, Goodnough T et al. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005; 11:565-74.
84. Halm EA, Wang JJ, Boockvar K et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma. 2004; 18:369-374.